XML 40 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating activities      
Net loss $ (200,368) $ (207,298) $ (146,227)
Adjustments to reconcile net loss to net cash used in operating activities      
Depreciation expense 19,221 12,254 6,769
Noncash lease expense 7,227 7,028 3,266
Share-based compensation expense 55,477 43,251 24,761
Intangible assets amortization 1,699 1,699 1,703
Investment amortization 741 7,233 773
Research and development inventory reserve 2,638    
Noncash interest expense 985    
Other (19) (78) 71
Changes in operating assets and liabilities      
Accounts receivable, net (22,648) (7,362) 2,613
Inventory 817 (5,200) (4,994)
Prepaid expenses and other current assets 3,551 1,286 (1,362)
Accounts payable and accrued liabilities 7,111 3,940 7,495
Operating lease right-of-use assets and liabilities (4,050) 8,522 (886)
Deferred revenue (56,496) (57,727) (43,389)
Other 169 (275) (276)
Net cash used in operating activities (183,945) (192,727) (149,683)
Investing activities      
Purchases of property and equipment (16,349) (61,746) (18,803)
Purchases of marketable securities (278,778) (316,544) (694,965)
Proceeds from sales and maturities of marketable securities 298,032 559,500 596,724
Net cash provided by (used in) investing activities 2,905 181,210 (117,044)
Financing activities      
Proceeds from exercise of stock options 7,890 26,717 21,748
Proceeds from public offering of common stock, net of underwriting discounts and commissions     272,160
Payment of public offering costs, net     (321)
Proceeds from revenue interest purchase agreement, net of issuance costs 124,375    
Proceeds from initial capital contributions for Digital Biotechnologies, Inc.   429  
Net cash provided by financing activities 132,265 27,146 293,587
Net (decrease) increase in cash, cash equivalents and restricted cash (48,775) 15,629 26,860
Cash, cash equivalents and restricted cash at beginning of year 141,203 125,574 98,714
Cash, cash equivalents and restricted cash at end of year 92,428 141,203 125,574
Noncash investing and financing activities      
Purchases of equipment included in accounts payable and accrued liabilities 1,719 $ 682 4,679
Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases     $ 36,607
Supplemental disclosure of cash flow information      
Cash paid for interest $ 494